Health X transcript confirms FY30 revenue target of ₹6,000 cr
The Q4 FY26 earnings call transcript, published June 19, also details ₹234 cr capex and JITO private-label sales at ₹30 lakhs/month. No material new information beyond the earlier call.
— 4 earlier stories on Health X Platform Ltd. →What's new
- Transcript of Q4 FY26 earnings call published on June 19, 2026.
- Management reaffirmed ₹6,000 cr FY30 revenue ambition (₹4,000 cr B2B, ₹2,000 cr B2C).
- Capex of ₹234 cr for new warehouses; JITO generic medicines at ₹30 lakhs monthly sales.
Why this matters
The transcript adds no fresh numbers beyond the June 12 call, but it provides a permanent record of management's strategic roadmap. The challenge: turning a ₹374 cr quarterly revenue base with a ₹13 cr net loss into a ₹6,000 cr profitable business by FY30.
What we're watching
- JITO monthly sales trajectory — ₹30 lakhs is early-stage; scalability is key.
- Progress on the B2B Shakti division, targeted to contribute ₹4,000 cr.
- Any profitability inflection given the current net loss.
The full read
Health X published the transcript of its Q4 FY26 earnings call. It confirms the already-telegraphed ₹6,000 crore FY30 revenue target split between B2B and B2C. The document also details ₹234 crore in capex for new warehouses and early JITO traction at ₹30 lakhs monthly sales. The transcript is a procedural disclosure, nothing market-moving emerges beyond what management said on the June 12 call. A routine filing. The open question remains: how the company bridges from the current ₹374 crore quarterly revenue and ₹13 crore net loss to a ₹6,000 crore ambition.
Questions answered
- What is the FY30 revenue target for Health X Platform?
- The company reaffirmed a target of ₹6,000 crores by FY30, split into ₹4,000 crores from B2B Retailer Shakti and ₹2,000 crores from B2C operations.
- How much capex is planned and for what?
- Health X plans capital expenditure of ₹234 crores for new warehouses as part of its expansion strategy.
- What is JITO and how is it performing?
- JITO is Health X's private-label generic medicines brand. In its first quarter of launch, it recorded monthly sales of ₹30 lakhs.
- Why is this transcript considered routine?
- The transcript is a compliance disclosure of the June 12 earnings call. All key guidance — including the ₹6,000 cr target and capex — had already been reported in prior coverage. No new material information was added.
- What was Health X's latest quarterly revenue and profit?
- For the quarter ended March 2026 (Q4 FY26), Health X reported sales of ₹374 crores and a net loss of ₹13 crores.
- What is the demerger update mentioned in the transcript?
- The transcript includes Q&A on the ongoing demerger of the financial services business, but no specific new milestone or timeline was disclosed.
Health X Platform Ltd.
Latest quarter · Mar 2026
Leverage & growth
Story so far
All notes on HEALTHX →- 19 Jun 2026 · 1:50 PM IST Health X transcript confirms FY30 revenue target of ₹6,000 cr
- 24d ago Health X targets ₹6,000 cr FY30 revenue, Q1 hits ₹400 cr
- 26d ago Health X splits its tiny finance arm, absorbs core healthcare unit into parent
- 31d ago Health X promoter sheds 0.79% stake for ₹7.5 cr
- 45d ago Health X Platform sets date for FY26 results